Daxor Corporation Closes Q4 2023 With Growth In New Sales To Hospital Systems And Increased Utilization Of Its BVA-100 Blood Volume Diagnostic Across The U.S. At Existing Accounts
Portfolio Pulse from Benzinga Newsdesk
Daxor Corporation (NASDAQ:DXR) reported growth in Q4 2023 through new sales of its BVA-100 Blood Volume Diagnostic analyzers to hospital systems and increased utilization at existing accounts across the U.S. The company's ezBVA Lab Service was highlighted as a key factor in driving this growth and adoption. Sales wins included analyzer purchases and rentals at major healthcare systems in Georgia, Wisconsin, and a multi-state academic health center, as well as an extension of the ezBVA Lab service in New Jersey. CEO Michael Feldschuh emphasized the company's focus on broadening commercial reach and improving patient outcomes.
February 07, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daxor Corporation reported significant growth in Q4 2023, driven by new sales and increased utilization of its BVA-100 Blood Volume Diagnostic analyzers and ezBVA Lab Service.
The reported growth and strategic sales wins in Q4 2023 for Daxor Corporation, including the expansion of its ezBVA Lab Service and the adoption of its BVA-100 analyzers by major healthcare systems, indicate a positive outlook for the company. These developments are likely to boost investor confidence and potentially lead to an increase in stock price in the short term, given the expansion in commercial reach and the emphasis on improving patient outcomes.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100